Immuno-Oncology
4-1BB: An Established Target for Cancer Immunotherapy
Following on from OX40, our TNF superfamily posts continue with 4-1BB, another important target in T cell co-stimulation.
One of the most critical changes Alex observed over his 30-year career in CROs is how customer needs and expectations have evolved from a pair of hands to subject matter experts. According to Alex, early CROs were perceived as essential facilitators, carrying out routine tasks for clients. Over time, however, a substantial increase in outsourcing led to CROs' explosive growth, transforming them into respected organizations renowned for their expertise.
The rapid growth in the CRO industry was partly driven by evolving client needs, leading to significant consolidation within the industry. Today's industry giants reflect this trend, with many CROs tracing their heritage back to multiple smaller companies, each contributing their unique expertise.
Despite the accelerated shift towards consolidation, Alex notes that CROs are now broadening their scope, moving from niche expertise to a wider range of services. This transformation enhances CROs' ability to address their clients’ unique challenges and deliver bespoke solutions.
As CROs expand their global footprint, the question of local vs. global relevance comes into sharp focus. According to Alex, the answer is complex, with multiple factors at play such as ease of shipping test articles, cost, and the need for specific expertise. The ideal solution often involves a balance of local and global presence, allowing for flexibility and a tailored approach to individual client needs.
Overall, Alex's insightful interview provides a fascinating snapshot of the shifting CRO industry, emphasizing how these trends are shaping the future of drug discovery and development. As the CRO industry continues to evolve and adapt, it's clear that the role of a strategic partner will not be lessening in time soon.
Crown Bioscience, (2025) Preclinical CRO Evolution: Insights from on Industry Transformation - Crown Bioscience. https://blog.crownbio.com/crowncast/beyond-the-lab-the-evolution-of-cros
Following on from OX40, our TNF superfamily posts continue with 4-1BB, another important target in T cell co-stimulation.
Following our post covering the Tumor Necrosis Factor Superfamily of Ligands and Receptors, we’re going to take a closer look at specific family membe…
Humanized mice, encompassing human tumors and human immune cells engrafted on immunodeficient mice, have been widely used for many years in immuno-onc…